Results 101 to 110 of about 86,128 (305)

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa   +12 more
wiley   +1 more source

Estimation in interval censored data

open access: yes, 2020
Interval censored failure time data occur in many areas including medicine, economics, zoology, psychology, sociology and engineering. In such studies, the variable of interest is often not exactly observed, but known to fall within some interval.
openaire   +1 more source

Survival Models with Interval Censored Data

open access: yes, 2020
Sansürleme, sağkalım analizi diğer istatistiksel yöntemlerden ayıran en önemli özelliktir. Sansürleme türleri ise sağdan, soldan ve aralıklı sansürleme olarak sınıflandırılmaktadır. Sağkalım analizinde kullanılan modellerin çoğu gözlemlerin sağdan sansürlü olduğu veri kümeleri için geliştirilmiştir.
ERÖZ, İlknur, ATA, Nihal
openaire   +1 more source

Multifactor Risk Stratification for Post‐Transplant Alcohol Relapse Using Abstinence, Psychosocial, and Socioeconomic Factors

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Alcohol relapse after liver transplantation is difficult to predict using abstinence duration alone. We developed a multifactor model integrating abstinence duration, psychosocial risk (SIPAT), and socioeconomic context (AUC 0.70). This approach may support individualized risk assessment and tailored follow‐up intensity; external validation is needed ...
Ayato Obana   +9 more
wiley   +1 more source

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma   +9 more
wiley   +1 more source

Research on Quantile Regression Method for Longitudinal Interval-Censored Data Based on Bayesian Double Penalty

open access: yesMathematics
The increasing prominence of the problem of censored data in various fields has made studying how to perform parameter estimation and variable selection in censored mixed-effects models one of the hotspots of current research.
Ke Zhao, Ting Shu, Chaozhu Hu, Youxi Luo
doaj   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki   +9 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

open access: yesBJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy